

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No. **5,776,456**
Serial No.: **08/ 476,275**
Confirmation No.: **4717**
Filed: **7 June 1995**
Applicant: **Darrell R. ANDERSON et al.**

For: Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma

Mail Stop Post Issue
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT BY ASSIGNEE UNDER 37 C.F.R. § 3.73(b)

Further to the power of attorney filed 3 November 2006, the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned patent by virtue of assignments of U.S. Patent No. 5,736,137 as recorded in the Patent and Trademark Office:

From the inventors to IDEC Pharmaceuticals Corp.,	recorded at Reel 006850, Frame 0468;
From IDEC Pharmaceuticals Corp. to Merrill Lynch/Morgan Stanley Associates. L.P.,	Reel 007171, Frame 0587;
From Merrill Lynch/Morgan Stanley Associates, L.P. to IDEC Pharmaceuticals Corp.,	Reel 007934, Frame 0284.


The following documents regarding the '137 patent are also recorded in the Office:

From IDEC Pharmaceuticals Corp. in favor of Silicon Valley Bank as collateral agent for Venture Lending & Leasing, Inc., granting a security interest,	recorded at Reel 007279, Frame 0680;
From Venture Lending & Leasing, Inc. in favor of IDEC Pharmaceuticals Corp., releasing all security interests,	Reel 010340, Frame 0869.

This application is a divisional of application serial no. 08/149,099, now U.S. Patent No. 5,736,137. Assignments of the '137 patent have effect as to this application. M.P.E.P. § 306. Biogen Idec Inc. is the successor in interest to IDEC Pharmaceuticals Corp.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,


Christopher A. Dayton
Associate General Counsel, IP
Biogen Idec Inc.

 Date